


correctness of any rejection of the relevant claims; Applicant explicitly reserves the right to pursue claims of similar or identical scope to those originally pending in this case in one or more other applications. In light of these amendments and remarks, Applicant respectfully submits that the claims are now in condition for allowance.

Applicant also acknowledges the request for new formal drawings, and will have such drawings prepared in a timely fashion.

It is Applicant's understanding that there are no fees associated with this matter. Should this understanding be in error, please charge any fees to our Deposit Account No. 03-1721.

Respectfully submitted,

Dated: 4/26/2002



Brenda Herschbach Jarrell, Ph.D.
Registration No. 39,223

Attorney for Applicant
CHOATE, HALL & STEWART
53 State Street
Boston, MA 02109
Telephone: 617-248-5000
Facsimile: 617-248-4000

Appendix A
Version With Markings to Show Changes Made

6. A [The] composition [of claim 5] comprising:
isolated skeletal myoblasts; and
isolated fibroblast cells,
wherein the composition is cultured *in vitro* on a surface coated with poly L lysine and laminin in a medium comprising EGF.
7. A [The] composition [of claim 5] comprising:
isolated skeletal myoblasts; and
isolated fibroblast cells,
wherein the composition is cultured *in vitro* on a surface coated with collagen in a medium comprising EGF.
8. A [The] composition [of claim 1] comprising:
isolated skeletal myoblasts; and
isolated fibroblast cells,
wherein the composition is cultured *in vitro* a maximum of about 14 days.
9. A [The] composition [of claim 1] comprising:
isolated skeletal myoblasts; and
isolated fibroblast cells,
wherein the composition is cultured *in vitro* a maximum of about 7 days.
10. A [The] composition [of claim 5] comprising:
isolated skeletal myoblasts; and
isolated fibroblast cells,
wherein [the] cells in the composition are permitted to double about one time *in vitro* prior to transplantation.
12. The composition of claim [11] 10, wherein the cells are permitted to double less than about 10 times *in vitro* prior to transplantation.
14. A [The] composition [of claim 1] comprising:
isolated skeletal myoblasts; and
isolated fibroblast cells,
wherein the composition engrafts into cardiac tissue after transplantation into a subject.
18. A [The] composition [of claim 1] comprising:
isolated skeletal myoblasts; and
isolated fibroblast cells,
wherein the skeletal myoblast cells are engineered to express a GATA transcription factor.

Appendix B
Pending Claims After Entrance of Present Amendment

6. (Amended) A composition comprising:
isolated skeletal myoblasts; and
isolated fibroblast cells,
wherein the composition is cultured *in vitro* on a surface coated with poly L lysine and laminin
in a medium comprising EGF.
7. (Amended) A composition comprising:
isolated skeletal myoblasts; and
isolated fibroblast cells,
wherein the composition is cultured *in vitro* on a surface coated with collagen in a medium
comprising EGF.
8. (Amended) A composition comprising:
isolated skeletal myoblasts; and
isolated fibroblast cells,
wherein the composition is cultured *in vitro* a maximum of about 14 days.
9. (Amended) A composition comprising:
isolated skeletal myoblasts; and
isolated fibroblast cells,
wherein the composition is cultured *in vitro* a maximum of about 7 days.
10. (Amended) A composition comprising:
isolated skeletal myoblasts; and
isolated fibroblast cells,
wherein cells in the composition are permitted to double about one time *in vitro* prior to
transplantation.
11. The composition of claim 10, wherein the cells are permitted to double about 10 times *in vitro* prior to transplantation.
12. (Amended) The composition of claim 10, wherein the cells are permitted to double
less than about 10 times *in vitro* prior to transplantation.
13. The composition of claim 12, wherein the cells are permitted to double about 5 times *in vitro* prior to transplantation.
14. (Amended) A composition comprising:
isolated skeletal myoblasts; and
isolated fibroblast cells,
wherein the composition engrafts into cardiac tissue after transplantation into a subject.

15. The composition of claim 14, wherein angiogenesis is promoted in the cardiac tissue of the subject.

18. (Amended) A composition comprising:
isolated skeletal myoblasts; and
isolated fibroblast cells,
wherein the skeletal myoblast cells are engineered to express a GATA transcription factor.

19. The composition of claim 18, wherein the GATA transcription factor is GATA4 or GATA6.